UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close

AAMI TIR48

Quality Management System (QMS) Recommendations on the Application of the U.S. FDA’s CGMP Final Rule on Combination Products

active, Most Current
Buy Now
Organization: AAMI
Publication Date: 1 January 2015
Status: active
Page Count: 28
scope:

INCLUSIONS

This Technical Information Report (TIR) provides recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drugdevice, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA's final rule (21 CFR Part 4; 78 FR 4307, 2013-hereafter "The Rule" or "FDA's Final Rule"). These recommendations are intended to inform the adoption and application of CGMPs for combination products.

Exclusions

The TIR does not address topics outside the realm of CGMPs. Additionally, the TIR may inform practices for combination products marketed outside the United States, but it is not intended, or considered to address non-U.S. requirements comprehensively.

Document History

AAMI TIR48
January 1, 2015
Quality Management System (QMS) Recommendations on the Application of the U.S. FDA’s CGMP Final Rule on Combination Products
INCLUSIONS This Technical Information Report (TIR) provides recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based...

References

Advertisement